RESUMEN
AIM: Fetal blood contains higher concentrations of glutamate-oxaloacetate transaminase (GOT; a blood enzyme able to metabolize glutamate) than maternal blood. The aim of this study was to determine the relationship between GOT and glutamate levels in arterial blood samples from umbilical cord in control newborn infants and newborn infants with hypoxic-ischaemic insult and/or symptoms of hypoxia-ischemia after delivery. METHOD: A total of 46 newborn infants (28 females, 18 males) were prospectively included in the study. Twenty-three infants (18 females, five males) were included as control participants and 23 (10 females, 13 males) were included as newborn infants at risk of adverse neurological outcome (defined as umbilical blood with pH <7.1). RESULTS: Analysis of glutamate concentration and GOT activity in umbilical blood samples showed that newborn infants with pH <7.1 had higher levels of glutamate (142.4 µmol/L [SD 61.4] vs 62.8 µmol/L [SD 25.5]; p<0.001) and GOT (83.1 U/L [SD 60.9] vs 34.9 U/L [SD 18.2]; p<0.001) compared to newborn infants without fetal distress. Analysis of Apgar scores and blood pH values (markers of perinatal distress) showed that conditions of severe distress were associated with higher glutamate and GOT levels. INTERPRETATION: During fetal development, the ability of GOT to metabolize glutamate suggests that this enzyme can act as an endogenous protective mechanism in the control of glutamate homeostasis.
Asunto(s)
Aspartato Aminotransferasas/sangre , Asfixia Neonatal/sangre , Sangre Fetal/metabolismo , Ácido Glutámico/sangre , Hipoxia-Isquemia Encefálica/sangre , Asfixia Neonatal/enzimología , Estudios Transversales , Femenino , Sangre Fetal/enzimología , Humanos , Hipoxia-Isquemia Encefálica/enzimología , Recién Nacido , Masculino , Neuroprotección/fisiología , Neurotoxinas/sangreRESUMEN
Aluminium concentration in samples of total parenteral nutrition solutions and samples of their individual components were analysed to know the exposure to this element. The median aluminium content obtained for the total parenteral nutrition solutions was 105.7 microg/L; for their individual components, 10% calcium gluconate and 1M monopotasic phosphate were the most contaminated, as well as the 1M sodium bicarbonate. The great variability found in the aluminium content of solutions suggests that contamination occurs during the manufacturing process.
Asunto(s)
Aluminio/análisis , Electrones , Nutrición Parenteral , Temperatura , Espectrofotometría AtómicaRESUMEN
OBJECTIVE: To verify whether small-for-gestational-age (SGA) preterm newborns represent a special risk group for carnitine deficiency. Secondary outcome includes assessment of longitudinal differences of total carnitine (TC), free carnitine (FC) and acylcarnitines between SGA and appropriate-for-gestational-age (AGA). METHODS: A retrospective study to evaluate carnitine and acylcarnitines profile on 144 very-low-birth weight newborns (VLBW), classified as AGA (n = 73) and SGA (n = 71), was performed by tandem mass spectrometry, during their first 5 weeks of life. Carnitine deficiency was defined as FC <40 µmol/L and FC/TC <0.7. RESULTS: Carnitine deficiency was observed in the two study groups throughout the monitoring period (maximum FC: 36.05 µmol/L in AGA and 32.24 µmol/L in SGA). FC/TC remains under 0.7 in both with progressive improvement. Unlike expected, a comparatively higher value of TC, FC and total acylcarnitines (tAC) was found in SGA during the first 2 weeks, with significant relevance on day 3-5, especially for tAC (p < 0.001). The only acylcarnitine with persistently lower value in SGA is C5 (p < 0.05 in first 2 weeks). CONCLUSIONS: A carnitine deficiency was demonstrated in all VLBW. Although birth weight restriction has been suggested as a risk factor for impaired carnitine status, in our study, SGA was not related with higher carnitine deficiency.
Asunto(s)
Carnitina/deficiencia , Recien Nacido Prematuro/sangre , Recién Nacido Pequeño para la Edad Gestacional/sangre , Recién Nacido de muy Bajo Peso/sangre , Femenino , Humanos , Recién Nacido , Masculino , Estudios RetrospectivosRESUMEN
BACKGROUND: With over 50 different disorders and a combined incidence of up to 1/3000 births, lysosomal storage diseases (LSDs) constitute a major public health problem and place an enormous burden on affected individuals and their families. Many factors make LSD diagnosis difficult, including phenotype and penetrance variability, shared signs and symptoms, and problems inherent to biochemical diagnosis. Developing a powerful diagnostic tool could mitigate the protracted diagnostic process for these families, lead to better outcomes for current and proposed therapies, and provide the basis for more appropriate genetic counseling. METHODS: We have designed a targeted resequencing assay for the simultaneous testing of 57 lysosomal genes, using in-solution capture as the enrichment method and two different sequencing platforms. A total of 84 patients with high to moderate-or low suspicion index for LSD were enrolled in different centers in Spain and Portugal, including 18 positive controls. RESULTS: We correctly diagnosed 18 positive blinded controls, provided genetic diagnosis to 25 potential LSD patients, and ended with 18 diagnostic odysseys. CONCLUSION: We report the assessment of a next-generation-sequencing-based approach as an accessory tool in the diagnosis of LSDs, a group of disorders which have overlapping clinical profiles and genetic heterogeneity. We have also identified and quantified the strengths and limitations of next generation sequencing (NGS) technology applied to diagnosis.
Asunto(s)
Enfermedades por Almacenamiento Lisosomal/diagnóstico , Análisis de Secuencia de ADN , Humanos , Enfermedades por Almacenamiento Lisosomal/genéticaRESUMEN
BACKGROUND AND OBJECTIVE: To evaluate clinical, biochemical and genetic findings of two series of patients with biotinidase deficiency. PATIENTS AND METHOD: Fifteen cases detected through newborn screening and six through selective screening for hearing loss or metabolic disease. RESULTS: No patient detected by neonatal screening had symptoms and only one case with partial biotinidase activity developed myoclonic seizures that resolved with biotin. More common mutations found among this group were p.D444H and the double mutation [p.D444H;p.A171T]. However, neurological and hearing manifestations predominated among the six symptomatic cases and mutations p.L32fs, p.G34fs, p.T401I, p.D444H, p.T532M and the novel one p.L466fs were identified. Patients with profound biotinidase deficiency and/or clinical signs were treated with pharmacological doses of biotin (10-30mg daily). CONCLUSION: Biotinidase deficiency must be included in the newborn screening programmes in order to begin early treatment even in partial forms. Different mutations found in both series of patients suggest that routine genetic procedure of the BTD gene by direct sequencing might be useful to assign patients to the partial or profound form of the disease.
Asunto(s)
Biotina/uso terapéutico , Deficiencia de Biotinidasa/diagnóstico , Tamizaje Neonatal , Complejo Vitamínico B/uso terapéutico , Adolescente , Biotinidasa/sangre , Biotinidasa/genética , Deficiencia de Biotinidasa/sangre , Deficiencia de Biotinidasa/tratamiento farmacológico , Deficiencia de Biotinidasa/genética , Preescolar , Pérdida Auditiva/diagnóstico , Humanos , Lactante , Recién Nacido , Enfermedades Metabólicas/diagnóstico , MutaciónAsunto(s)
Grasas de la Dieta/farmacocinética , Ácidos Grasos Esenciales/fisiología , Ácidos Grasos Insaturados/fisiología , Alimentos Infantiles , Lactancia/fisiología , Política Nutricional , Embarazo/metabolismo , Adulto , Ácidos Araquidónicos/metabolismo , Desarrollo Infantil/fisiología , Grasas de la Dieta/administración & dosificación , Eicosanoides/metabolismo , Ácido Graso Desaturasas/metabolismo , Ácidos Grasos Esenciales/metabolismo , Ácidos Grasos Esenciales/farmacocinética , Ácidos Grasos Insaturados/metabolismo , Ácidos Grasos Insaturados/farmacocinética , Femenino , Feto/metabolismo , Aceites de Pescado/efectos adversos , Contaminación de Alimentos , Humanos , Sistema Inmunológico/crecimiento & desarrollo , Lactante , Alimentos Infantiles/normas , Fórmulas Infantiles/normas , Recién Nacido , Ácido Linoleico/farmacocinética , Redes y Vías Metabólicas , Compuestos de Metilmercurio/efectos adversos , Leche Humana/metabolismo , Necesidades Nutricionales , Ensayos Clínicos Controlados Aleatorios como Asunto , Ácido alfa-Linolénico/farmacocinéticaRESUMEN
Fundamento y objetivo: Comparar los datos clínicos, bioquímicos y genéticos de dos series de pacientes con deficiencia de biotinidasa. Pacientes y métodos:Quince casos detectados en el cribado neonatal y seis en el cribado selectivo para sordera o para enfermedades metabólicas hereditarias. Resultados: Ningún caso detectado en el cribado neonatal presentaba síntomas y sólo uno con deficiencia parcial desarrolló convulsiones que cedieron con biotina. La mutación p.D444H y la doble mutación [p.D444H; p.A171T] fueron las más frecuentes en este grupo. Sin embargo, los seis pacientes diagnosticados en el cribado selectivo presentaban síntomas neurológicos y las mutaciones detectadas fueron p.L32fs, p.G34fs, p.T401I, p.D444H, p.T532M y p.L466fs. Todos los pacientes con síntomas o con deficiencia profunda de biotinidasa se trataron con dosis farmacológicas de biotina (10-30mg/día). Conclusión: La deficiencia de biotinidasa debe incluirse en los programas de cribado neonatal con el fin de tratar precozmente incluso las formas parciales. Las diferentes mutaciones identificadas en las dos series de pacientes indican que el análisis genético mediante secuenciación directa del gen BTD sería útil para el diagnóstico rápido de las formas parciales o profundas de la enfermedad (AU)
Background and objetive: To evaluate clinical, biochemical and genetic findings of two series of patients with biotinidase deficiency.Patients and method: Fifteen cases detected through newborn screening and six through selective screening for hearing loss or metabolic disease. Results: No patient detected by neonatal screening had symptoms and only one case with partial biotinidase activity developed myoclonic seizures that resolved with biotin. More common mutations found among this group were p.D444H and the double mutation [p.D444H;p.A171T]. However, neurological and hearing manifestations predominated among the six symptomatic cases and mutations p.L32fs, p.G34fs, p.T401I, p.D444H, p.T532M and the novel one p.L466fs were identified. Patients with profound biotinidase deficiency and/or clinical signs were treated with pharmacological doses of biotin (10-30mg daily).Conclusion: Biotinidase deficiency must be included in the newborn screening programmes in order to begin early treatment even in partial forms. Different mutations found in both series of patients suggest that routine genetic procedure of the BTD gene by direct sequencing might be useful to assign patients to the partial or profound form of the disease (AU)
Asunto(s)
Humanos , Masculino , Femenino , Recién Nacido , Deficiencia de Biotinidasa/genética , Errores Innatos del Metabolismo/genética , Biotina/uso terapéutico , Tamizaje Neonatal , Sordera/etiología , Convulsiones/etiología , MutaciónRESUMEN
No disponible